Program Slides Download (PDF)
A recent paradigm shift in the role of surgical oncologists in the management of breast cancer patients has seen an increasing number of these clinicians making treatment choices as to whether a patient needs neoadjuvant or adjuvant therapy based on surgical outcomes. There have also been significant changes in the treatment landscape for breast cancer with the approval of several new agents and new indications for previously approved agents.
Therefore, there is a growing need for education targeting surgical specialists to inform them of updated staging guidelines for breast cancer, the role of biomarkers in choosing treatment options, and the safety and efficacy profiles of novel targeted agents for breast cancer. This program will give surgical oncologists an update on these novel treatment options and allow clinicians to better collaborate with their colleagues on the multidisciplinary cancer care team, ultimately improving the quality of care for their patients with breast cancer.
This presentation was selected by the Society of Surgical Oncology as an independent educational activity held at the site of the 2014 Annual Cancer Symposium. This presentation is not sponsored or endorsed by the Society of Surgical Oncology.
Monica Morrow, MD
Chief, Breast Service
Department of Surgery
Anne Burnett Windfohr Chair of Clinical Oncology
Professor of Surgery, Weill Medical College of Cornell University
New York, NY
W. Fraser Symmans, MD
Professor of Pathology
University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Professor of Medicine
Co-leader, Women's Cancers Program
University of Southern California
USC/Norris Comprehensive Cancer Center
Los Angeles, CA
This program is intended for surgical oncologists and other health care professionals who are involved in the care of patients with breast cancer.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Evaluate the role of biomarkers and genomic testing in personalizing therapy for breast cancer
- Integrate principles of pathological assessment, systemic therapy and surgical management in the multi-disciplinary care of breast cancer
- Review the quality measures associated with personalized treatment for breast cancer
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Method of Participation
To receive continuing medical education (CME) and MOC Part II certification credit, participants must view the content, successfully complete the self-assessment exam and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the corresponding rationale. Learners will be able to review the content and repeat the self-assessment exam as many times needed. Upon achieving a score of 75% or higher on all of the modules, learners will be asked to complete a post-activity evaluation. A CME/MOC certificate will be sent via e-mail upon successful submission of the post-activity evaluation.
There is no fee for this program.
ESTIMATED TIME TO COMPLETE ACTIVITY
The estimated time to complete this entire activity is 1 hour.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Maintenance of Certification (MOC) Credit is only for surgeons who are involved in the treatment of patients with cancer. The Potomac Center for Medical Education under the American Board of Surgery MOC Criteria has approved this activity for up to 1 MOC Part II certification points.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Monica Morrow, MD – Nothing to Disclose
W. Fraser Symmans, MD – Owns stock in: Amgen, Isis Pharmaceuticals, Nuvera Biosciences
Debu Tripathy, MD – Research: Genentech
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Latha Shivakumar, PhD, CCMEP; Blair St. Amand; Jay Katz, CCMEP; CME Peer Review: Nothing to Disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Jointly Sponsored By
This educational activity is supported by an educational grant from:
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.